Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786751 | 0.80 | TUBB4A (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL723249 | 0.75 | NR1H2 (0.41) | GABRA2GABRB2KMT2AALDH1A1LMNA | |
| SCHEMBL12380473 | 0.73 | ALDH1A1 (0.67) | KMT2AALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL724186 | 0.72 | MAPT (0.46) | GABRA2GABRB2KMT2AALDH1A1LMNA | |
| SCHEMBL2966992 | 0.71 | ALDH1A1 (0.76) | KMT2AALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL14407932 | 0.71 | ALDH1A1 (0.76) | KMT2AALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL724434 | 0.70 | ALDH1A1 (0.42) | KMT2AALDH1A1LMNASMN1; SMN2TDP1 | |
| SCHEMBL786666 | 0.70 | ALDH1A1 (0.62) | KMT2AALDH1A1LMNANPC1RAB9A | |
| SCHEMBL12224046 | 0.70 | ALDH1A1 (0.62) | KMT2AALDH1A1LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL724182 | 0.69 | ALDH1A1 (0.41) | KMT2AALDH1A1LMNASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196632-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021203100-A9 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021203100-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | F2 4793/4885PLAU 1220/4885ELANE 956/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | F2 4793/4885PLAU 1220/4885ELANE 956/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | F2 4775/4885PLAU 3641/4885ELANE 889/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | F2 1274/4885PLAU 3078/4885ELANE 2650/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | F2 4793/4885PLAU 1220/4885ELANE 956/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | F2 4355/4885PLAU 714/4885ELANE 751/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | F2 4793/4885PLAU 1220/4885ELANE 956/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | F2 4355/4885PLAU 714/4885ELANE 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.